Open AccessGene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Author(s) -
Richard F. Schlenk,
Konstanze Döhner,
Michael Kneba,
Katharina Götze,
Frank Hartmann,
Francesco del Valle,
Heinz Kirchen,
Elisabeth Koller,
J T Fischer,
Lars Bullinger,
Marianne Habdank,
Daniela Späth,
Silja Groner,
B. P. Krebs,
Sabine Käyser,
Andrea Corbacioglu,
Andreas Anhalt,
Axel Benner,
Stefan Fröhling,
Hartmut Döhner
Publication year - 2009
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.13378
Subject(s) - npm1 , cebpa , myeloid leukemia , acute promyelocytic leukemia , medicine , oncology , cancer research , fms like tyrosine kinase 3 , cytogenetics , biology , gene mutation , retinoic acid , mutation , genetics , karyotype , gene , chromosome
In a previous randomized trial, AML HD98B, we showed that administration of all-trans retinoic acid in addition to intensive chemotherapy improved the outcome of older patients with acute myeloid leukemia. The objectives of this study were to evaluate the prognostic impact of gene mutations and to identify predictive genetic factors for the all-trans retinoic acid treatment effect.